Akela Pharma to repeat Fentanyl TAIDUN tests at request of FDA

Akela Pharma have announced that it will repeat required inhalation toxicology studies at the request of the FDA before commencing long term safety Phase III trials

Univ Maryland publish series of Nociceptin/Orphanin FQ(1−13) Amide Analogues

Researchers at the University of Maryland have published a series of cyclic analogues with a lactam linkage that are biologically active conformation(s) of nociceptin/orphanin FQ (N/OFQ).

Phase I data show Theravance LAMA GSK1160724/TD-4208 safe in COPD patients

Theravance have announced Phase 1 data showing its long acting muscarinic antagonist (LAMA), GSK1160724/TD-4208 to be safe and well tolerated in the treatment of chronic obstructive pulmonary disease (COPD). Partner GSK have, however, informed Theravance that it intends to return the LAMA program to Theravance because the current formulation of TD-4208 is incompatible with GSK’s [...]

Zealand Pharmaceutical’s GLP-1 Agonist AVE0010 enters Phase III trials in Patients With Type 2 Diabetes

Zealand Pharmaceutical’s GLP-1 Agonist AVE0010 enters Phase III trials in Patients With Type 2 Diabete

MAP Pharmas 5-HT1D agonist enter Phase III for migraine

MAP Pharmaceuticals has initiated its first Phase 3 trial of MAP0004 its 5-HT1D agonist for the treatment of Migraine

Glenmarks CB2 agonist GRC 10693 to enter phase I trials

Glenmark Pharmaceuticals have announced that its CB2 agonist GRC-10693 is entering Phase I trials for neuropathic, osteoarthritis and other inflammatory pain.

Icatibant approved in EU for hereditary angioedema (HAE)

Jerini/Shire have announced the that the European Commission has granted the company marketing authorization for its lead compound Icatibant (Firazyr) in the treatment of acute attacks of hereditary angioedema (HAE).

Orexigen to initiate second Phase IIb trial of Empatic

Orexigen have announced that they are to commence a second Phase IIb clinical trial for Empatic (zonisamide and bupropion)

Theravance annouces positive Phase II results of MABA GSK961081 in COPD

Theravance/GSK have announced positive results from a Phase II study of GSK961081 for the treatment of chronic obstructive pulmonary disease (COPD). The successful achievement of proof-of-concept in the MABA Phase 2 clinical study triggers a milestone payment of $10 million from GSK.